Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

Half-maximal inhibitory concentration (IC₅₀), half-maximal cytotoxic concentration (CC₅₀), and selectivity index (SI) of CTLL formulation and its ingredients. by Prapaporn Chaniad (9761710)

Half-maximal inhibitory concentration (IC₅₀), half-maximal cytotoxic concentration (CC₅₀), and selectivity index (SI) of PSCD formulation and its ingredients. by Prapaporn Chaniad (9761710)

Hyperalgesia was assessed by a decrease in paw withdrawal threshold (PWT_50%) in a model of mild heat injury (MHI). by Manuel P. Pereira (417488)

Proportion of participants with sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment value and to < 8100 mf/ml. by Joseph Kamgno (81039)

“…<p>Proportion of participants with sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment value and to < 8100 mf/ml.…”

Concentration of DRS-B2 that inhibits 50% cell growth (GI₅₀) extracted from S2 Fig. by Célia Dos Santos (306471)

GSK343 decreased tumor stemness. by Laura V. Bownes (10276762)

“…Treatment with GSK343 significantly decreased tumorsphere formation by both the COA3 (A) and COA6 (B) cells, representing a decrease in stem cell-like phenotype. …”

KOR-agonist (U50'488) and MOR-agonist (DAMGO) decrease symptoms in OVA-allergic mice. by Swantje C. Duncker (154707)

Multinomial logistic model of the effects of a cluster of phenolic compounds on host and parasitoid survival across development among larvae that survived to at least 50 mg. by Noah H. Rose (703745)

Herbicide doses corresponding to 20 and 50% plant growth reduction of canola, chickpea, and wheat. by Win Win Pyone (20396432)

Decrease in vRNA in brain during antiretroviral therapy. by Sonny R. Elizaldi (9684796)

The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

Concentration of DRS-B2 and [W/F]³-DRS-B2 that inhibits 50% of cell growth (GI₅₀) extracted from Fig 12. by Célia Dos Santos (306471)

Regions of significantly decreased ACM of SP-MS relative to RR-MS patients. by Mark Lyksborg (583318)

Olaparib reverses the oxLDL-mediated decrease in co-immunoprecipitation of IκBα with RelA or p50. by Khamis Mustafa (17941332)

“…Relative band densities from three independent experiments were analyzed. (A) OxLDL decreased co-immunoprecipitation of IκBα with both RelA and p50, and olaparib reversed the effect of oxLDL on the dissociation of IκBα with RelA and p50. …”

Trial profile. by Chanel Avenant (409756)

Subjects:

Effect of essential oil TTO and LEO coating of MWCNT filters on bacterial removal rates. by Xiuli Dong (658906)

Subjects:

Essential oil-incorporated carbon nanotubes filters for bacterial removal and inactivation - Fig 4 by Xiuli Dong (658906)

Subjects:

Inactivation rate of the LEO-MWCNTs filters to <i>E</i>. <i>coli</i> cells captured on the filters with different incubation time after the filtering step. by Xiuli Dong (658906)

Subjects:

Log of <i>E</i>. <i>coli</i> cell numbers in filtrates after filtering through MWCNT filters with different MWCNT loadings. by Xiuli Dong (658906)

Subjects: